[Use of ceftriaxone in urinary and respiratory tract infections]

Area of Science:

• Infectious Diseases
• Pharmacology
• Pediatrics

Background:

• Severe urinary and respiratory tract infections pose significant health risks.
• Bacterial pathogens such as E. coli, S. pneumoniae, P. aeruginosa, P. mirabilis, and enterococci are common causes.
• Effective antibiotic treatment is crucial for managing these severe infections.

Purpose of the Study:

• To evaluate the efficacy and safety of ceftriaxone in treating severe urinary and respiratory tract infections.
• To assess the clinical outcomes and microbiological response to ceftriaxone therapy.
• To determine the tolerability and potential adverse effects of ceftriaxone in pediatric and adult patients.

Main Methods:

• A study involving 16 children (3-14 years) and 4 adults (17-70 years) with severe infections.
• Ceftriaxone administered as a single daily dose (50 mg/kg for children, 2.0 g for adults) for 7-10 days.
• Infections included pyelonephritis, pneumonia, and peritonitis caused by specified bacteria.

Main Results:

• All patients achieved clinical improvement with ceftriaxone treatment.
• Microbiological cultures became negative in 17 out of 20 patients.
• No adverse reactions or toxic effects on liver, renal, pancreatic, or bone marrow function were observed.

Conclusions:

• Ceftriaxone is a safe and effective treatment option for severe urinary and respiratory tract infections.
• The antibiotic demonstrated high efficacy in eradicating bacterial pathogens and achieving clinical resolution.
• Ceftriaxone can be safely administered without significant adverse events in both pediatric and adult populations.